Who We Are:

• Research and Development
• Management
• Board of Directors

KPI is a privately held drug company in Durham, NC founded in 1995 after acquisition of Burroughs Wellcome Co. by Glaxo Inc. The President and CEO of KPI, Thomas A. Krenitsky, Ph.D., was formerly the Vice President of Research at Burroughs Wellcome. Wayne R. Eberhardt, Vice President, Business Development and General Counsel, was formerly the Chief Patent Counsel at Burroughs Wellcome. The senior scientists of KPI are also former employees of Burroughs Wellcome with extensive experience and a proven record of accomplishment in drug discovery and development.

What We Do:

KPI has a therapeutic focus on disorders of the nervous system. Our efforts are directed toward drug discovery. Our drug candidates are available for license to other companies.

Drug Candidates Under Development

KP544: A small molecule modulator of nerve growth factor and cyclic AMP.

KP544 is available for license to another pharmaceutical company for clinical development, manufacture and marketing.

Stage of development: The drug is currently in Phase I.

Therapeutic use: Neurodegenerative conditions including mild cognitive impairment and Alzheimer’s disease. Treatment of chemically induced (Taxol) peripheral neuropathy.

Mechanism: KP544 is a downstream enhancer of the differentiation cascade initiated by nerve growth factor and cyclic AMP.

KP157: A selective and reversible monoamine oxidase-A inhibitor.

KP157 (also known as CX157) has been licensed to CeNeRx BioPharma under the brand name Tyrima.

Stage of development: Phase II clinical studies are in progress.

Therapeutic use: Depression and other conditions such as anxiety.

 

 

KP157

Contact Us